The Doping Control Review Board (DCRB) shall consist of eight persons appointed by the Bureau. A majority of the members of the DCRB shall be either physicians licensed in internal medicine, endocrinology, clinical pharmacology or sports medicine, with experience in antidoping practices or analytical chemists with experience in WADA accredited laboratories or their equivalent.

The DCRB may review and make recommendations to the Bureau regarding FINA’s doping control programme and may make proposals for additions or amendments to the Doping Control Rules for consideration by the Congress. The DCRB should also approve the Therapeutic Use Exemptions on behalf of FINA in accordance with the FINA Doping Control Rules and WADA Code.